MAIA Biotechnology, Inc. (MAIA) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.4 |
| Open | 1.4 |
| Day High | 1.4 |
| Day Low | 1.31 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.87 |
| Volume | 467,831 |
| Average Volume | 498,717 |
| Market Cap | 79.65M |
| PE | -2.11 |
| EPS | -0.62 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 1.49 |
| Change | -0.09 |
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Mar 04, 2026 9:00 PM GMT
Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceu
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Mar 03, 2026 3:45 AM GMT
Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceu
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Mar 02, 2026 10:00 PM GMT
CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has commence